阿帕替尼联合立体定向放射治疗用于前列腺癌骨转移治疗的研究

Application of apatinib combined with radiotherapy in the treatment of prostate cancer with bone metastasis

目的探讨阿帕替尼联合立体定向放射治疗(SBRT)用于前列腺癌骨转移治疗中有无协同抗肿瘤作用及其有效性、安全性的评估。方法选择前列腺癌骨转移受试者29例,分为试验组19例及对照组10例,分别给予250 mg阿帕替尼联合或不联合SBRT(剂量为6 gy/次,共计5次)治疗。疗效评价指标为癌痛评分及前列腺特异性抗原(PSA)的变化及不良反应(AE)发生的情况。结果试验组平均疼痛评分变化优于对照组。试验组患者出现PSA下降50%以上多于对照组,两组PSA下降持续时间均可达2~6月。放疗并未增加3级不良反应的发生。结论服用250 mg阿帕替尼联合SBRT可协同控制前列腺癌骨转移患者的病情及癌痛,不良反应可耐受,可进行大样本试验验证。

Objective Objective To Investigate whether there was a synergistic anti-tumor ettect of apatinib in combination ot stereotactic radiotherapy （SBRT） in the treatment of prostate cancer patients with bony metastasis ,and evaluate its efficacy and safety. Methods We selected 29 prostate cancer patients with bony metastasis and divided them into experimental group （n = 19 ） and con- trol group （n = 10）. The experimental group was given 250 mg apatinib daily combined with SBRT （6 Gy/fraction ,5 fraction in total） while the control group was given 250 mg apatinib daily alone. The changes in serum prostate specifc antigen （PSA） and pain relief as well as adverse reaction were compared between the two groups. Results The pain relief in the experimental group was superior to the control group. Patients with PSA declines of ≥50% in the experimental group were more than that in the control group. The duration of PSA decline was 2 ~ 6 months in the both groups. SBRT did not increase the rate of 3-degree adverse reaction. Conclusion Apatinib at dose of 250 mg daily in combination of RT synergized pain control. Further studies with large sample size are needed